跳至主要内容
临床试验/NCT07000825
NCT07000825Enrolling By Invitation不适用

EFFECTS OF INGESTING AN EXTRACT OR YERBA MATE (ILEX PARAGUARIENSIS) ON NUTRICIONAL, METABOLIC AND INFLAMMATORY PARAMETERS AND OXIDATIVE STATUS IN OVERWEIGHT INDIVIDUALS

Universidade Federal da Fronteira Sul1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2025年10月6日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
Enrolling By Invitation
发起方
入组人数
80
试验地点
1
主要终点
diabetes

研究概览

简要总结

Yerba mate (Ilex paraguariensis), a traditional drink consumed in different parts of the word, but especially in southern Brazil, is an importante source of polyphenols and has a high antioxidant potencial, With a moderate content of methylxanthines, yerba mate has stood out for its promising effects in modulating metabolic pathways in pre-clinical models. However, its beneficial effets in clinical trials have yet to be elucidated. Overweight and chronic non-communicable diases are urgent public health conditions and reducing the risk of these conditions through food sources is one of the most sustainable approaches. This study aims to evaluate the impact of a standardized extract of yerba mate on nutritional, biochemical, metabolic, inflammatory and antioxidant status parameters in overweight individuals compared to a placebo. A double-blind, parallel, randomized, placebo- controlled clinical trial will be conducted involving 80 overweight individuals. The subjects will receive an encapsulated yerba mate extract totaling 2,250 mg or a corresponding placebo, fractionated three times a day. This amount was defined according to previous studies thet estimated the habitual intake of yerba mate in the form of chimarrão or tererê by adults in a city in the southern region of the country. Anthropometric measurements, composition, blood pressure and blod and stool samples will be collected for nutritional assessment, metabolic and inflammatory parameters and antioxidant status assessment on days 0 and 90. The data will be analyzed descriptively and inferentially. Differences in the individuals characteristics at baseline and comparisons between groups will be aseessed using the difference of means test (depending on the normality of the data) and chi-square or Fisher-s exact test for categorical variabes, In addition, to compare the effect of the intervention between the groups, a two-way analysis of covariance will be used. A 5% significance level will be adopted. It is expect to find positive effects of yerba mate extract on the parameters assessed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
40 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •men and women;
  • •aged between 40 and 65 years;
  • •with no previous cardiovascular history;
  • •individuals who are non-smokers or who have stopped smoking in the last 3 years;
  • •individuals who agree to maintain a habitual diet and physical activity;
  • •individuals who agree to maintain habitual consumption of polyphenol-rich beverages (yerba mate, teas, coffee, wine, cocoa, soy milk and fruit juice) during the course of the study;
  • •individuals who are not taking hypoglycemic, antihypertensive or anticholesterolemic drugs and;
  • •individuals who are overweight or obese (BMI≥25 to 34 Kg/m2 );
  • •individuals who have given up nutritional monitoring at least 3 months or who are undergoing nutritional treatment, but who are not showing weight changes of >5% in the last 3 months.

排除标准

  • •diagnosis uncontrolled metabolic or endocrine pathologies;
  • •who have undergone obesity surgery;
  • •post-menopausal women;
  • •pregnant and breastfeeding women;
  • •use of antipsychotics;
  • •with a vegetarian or vegan diet;
  • •who use probiotics and food supplements with antioxidant characteristics;
  • •those who have had a weight change of more than 10% in the last 3 months; 9) in treatment for excess body weight (hypocaloric diet or current nutritional treatment);
  • •10) smokers or chronic alcoholics; 11) Severe hypertension, history of cardiovascular disease with clinical complications such as: acute myocardial infarction and other coronary heart disease; 12) individuals with known malignant neoplasms, gastrointestinal diseases, kidney disease and/or liver disease.

研究组 & 干预措施

Intervention (yerba mate)

Experimental

2,250 mg of standardized yerba mate extract will be administered in 9 capsules, 3 times a day, just before the main meals.

干预措施: Intervention with yerba mate extract or placebo (Dietary Supplement)

Test (yerba mate)

Placebo Comparator

9 capsules containing maltodextrin will be administered 3 times a day, just before the main meals.

干预措施: Intervention with yerba mate extract or placebo (Dietary Supplement)

结局指标

主要结局

diabetes

时间窗: 12 weeks

measured by plasma glucose, fructosamine and C peptide

body mass index

时间窗: 12 weeks

measured by weight in kilograms and height in meters

fat percentage

时间窗: 12 weeks

measured by electrical bioimpedance

abdominal fat

时间窗: 12 weeks

measured by waist circumference

dyslipidemia

时间窗: 12 weeks

measured by lipid profile

次要结局

  • inflamation(12 weeks)
  • oxidative stress(12 weeks)
  • transcriptome(12 weeks)
  • gut microbiota(12 weeks)
  • Iron metabolism(12 weeks)
  • metabolism(12 weeks)

研究者

发起方
Universidade Federal da Fronteira Sul
申办方类型
Other
责任方
Principal Investigator
主要研究者

Eloá Angélica Koehnlein

Professor

Universidade Federal da Fronteira Sul

研究点 (1)

Loading locations...

相似试验